WHY DO WE STILL NEED LARGE SCALE CLINICAL TRIAL: THE CASE OF N-3 PUFA
After the first reports about a protective effect on coronary heart disease (CHD) published more than 40 years ago, wide interest in the therapeutic use of n-3 polyunsaturated fatty acids (n-3 PUFA) aroused. Since then, many studies and meta-analyses have reported a significantly reduced risk of CHD...
Main Authors: | Roberto eMarchioli, Giacomo eLevantesi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2012-06-01
|
Series: | Frontiers in Physiology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fphys.2012.00202/full |
Similar Items
-
Current evidence linking polyunsaturated fatty acids (PUFAs) with cancer risk and progression
by: Maria eAzrad, et al.
Published: (2013-09-01) -
The role of polyunsaturated fatty acids (PUFA) in the formation of the structure and functions of biomembranes
by: A. P. Levitsky
Published: (2020-06-01) -
Association of Maternal Erythrocyte PUFA during Pregnancy with Offspring Allergy in the Chinese Population
by: Shanshan Peng, et al.
Published: (2022-05-01) -
Revisiting the Role of LXRs in PUFA Metabolism and Phospholipid Homeostasis
by: Antoine Jalil, et al.
Published: (2019-08-01) -
A Dynamic Model for Estimating the Interaction of ROS–PUFA–Antioxidants in Rabbit
by: Simona Mattioli, et al.
Published: (2022-03-01)